BioArctic

BioArctic Short-term Debt

The Short-Term Debt of BioArctic (BIOA B.ST) as of Nov 10, 2026 is 15.72 M SEK. In the previous year, Short-Term Debt was 13.15 M SEK — a change of 19.57% (higher).

Short-term Debt

15.72 MSEK

YoY

19.57%

Last updated:

Short-Term Debt of BioArctic is 2025 15.72 M SEK. Short-Term Debt of BioArctic was 2024 13.15 M SEK. It decreases by 19.57% higher compared to the previous year.

The BioArctic Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2018
-209.11 M SEK
Jan 1, 2019
-11.22 M SEK
Jan 1, 2020
-60.85 M SEK
Jan 1, 2021
8.09 M SEK
Jan 1, 2022
8.86 M SEK
Jan 1, 2023
2.83 M SEK
Jan 1, 2024
13.15 M SEK
Jan 1, 2025
15.72 M SEK
The BioArctic Short-term Debt history
YEARShort-term DebtYoY
15.72 MSEK+19.57%
13.15 MSEK+365.12%
2.83 MSEK-68.08%
8.86 MSEK+9.45%
8.09 MSEK-113.30%
-60.85 MSEK+442.31%
-11.22 MSEK-94.63%
-209.11 MSEK-55.82%
-473.31 MSEK—
0.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Short-Term Debt of BioArctic is 15.72 M SEK in 2025.

Short-Term Debt of BioArctic changed from 13.15 M SEK to 15.72 M SEK, representing a 19.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt BioArctic since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's BioArctic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioArctic

All Key Metrics — BioArctic